ID

34394

Beschrijving

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms; ODM derived from: https://clinicaltrials.gov/show/NCT01309789

Link

https://clinicaltrials.gov/show/NCT01309789

Trefwoorden

  1. 17-01-19 17-01-19 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

17 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
Beschrijving

ID.1

Datatype

boolean

measurable disease of at least 1.5 cm
Beschrijving

ID.2

Datatype

boolean

ecog performance status less than or equal to 2
Beschrijving

ID.3

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
Beschrijving

ID.4

Datatype

boolean

current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
Beschrijving

ID.5

Datatype

boolean

history of another primary malignancy that has not been in remission for at least 3 years
Beschrijving

ID.6

Datatype

boolean

left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Beschrijving

ID.7

Datatype

boolean

viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
Beschrijving

ID.8

Datatype

boolean

known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Lymphoma, Large-Cell, Anaplastic NCT01309789

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
treatment-naive cd30-positive mature t-cell and nk-cell neoplasms, including systemic anaplastic large cell lymphoma
boolean
ID.2
Item
measurable disease of at least 1.5 cm
boolean
ID.3
Item
ecog performance status less than or equal to 2
boolean
Item Group
C0680251 (UMLS CUI)
ID.4
Item
known cerebral/meningeal disease, including history of progressive multifocal leukoencephalopathy
boolean
ID.5
Item
current diagnosis of primary cutaneous anaplastic large cell lymphoma, mycosis fungoides, sezary syndrome or other primary cutaneous lymphomas; extranodal nk/t-cell lymphoma, nasal type
boolean
ID.6
Item
history of another primary malignancy that has not been in remission for at least 3 years
boolean
ID.7
Item
left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
boolean
ID.8
Item
viral, bacterial, or fungal infection within two weeks prior to the first dose of brentuximab vedotin
boolean
ID.9
Item
known human immunodeficiency virus (hiv), hepatitis b virus, or hepatitis c virus positive status
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial